The FDA approved pembrolizumab (Keytruda, Merck) for the first-line treatment of patients with stage III/IV non-small cell lung cancer (NSCLC) who are not candidates for surgery or definitive chemoradiation. The agency also approved pembrolizumab in combination with the tyrosine kinase inhibitor axitinib (Inlyta, Pfizer) for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
NSCLC Indication
The NSCLC indication requires that patients have tumors with no EGFR or ALK